As of Feb 20
| -0.01 / -2.17%|
The 1 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 0.60, with a high estimate of 0.60 and a low estimate of 0.60. The median estimate represents a +33.33% increase from the last price of 0.45.
The current consensus among 1 polled investment analysts is to Hold stock in Rosetta Genomics Ltd. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.